Timber Pharmaceuticals Inc. (AMEX:TMBR) saw a downside of -2.02% to $0.74 after subtracting -$0.02 on Wednesday. The 5-day average trading volume is 1,778,448 shares of the company’s common stock. It has gained $0.8600 in the past week. An average of 890,817 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 834,971.
TMBR’s 1-month performance is -17.11% or -$0.1900 on its low of $0.7200 reached on 10/13/21. The company’s shares have touched a 52-week low of $0.67 and high of $3.65, with the stock’s rally to the 52-week high happening on 03/11/21. YTD, TMBR has achieved 2.19% or -$0.0170. However, the current price is down -79.62%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Sep 02, 41 days have gone by since the last insider trading activity for Timber Pharmaceuticals Inc. (TMBR). TardiMed Sciences LLC (10% Owner) most recently sold 225,000 shares at $0.94 per share on Sep 02. This transaction cost the insider $210,960. 10% Owner, TardiMed Sciences LLC, sold 150,500 shares at a price of $0.92 on Sep 01. Then, on Aug 31, 10% Owner TardiMed Sciences LLC sold 150,000 shares at a price of $0.91 per share. This transaction amounted to $136,740.
The company’s PE ratio for the last five years has touched a high of 31.68 and a low of 19.23. TMBR stock has a beta of 0.13. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 31.64 while the price-to-book (PB) in the most recent quarter is 9.49.
Timber Pharmaceuticals Inc.’s quick ratio for the period ended April 29 was 3.00, with the current ratio over the same period at 3.00 meaning that TMBR stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending April 29 was 0.00, while the total debt to equity was 0.00. The firm’s gross profit as reported stood at $0.45 million against revenue of $0.45 million.
For the quarterly period ending April 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 100.0% to $0.39 million, while revenue of $40000.0 was 89.74% off the previous quarter. Analysts expected TMBR to announce -$0.84 per share in earnings in its latest quarter, but it posted -$1.34, representing a -59.50% surprise. EBITDA for the quarter stood at more than -$2.9 million. TMBR stock balance sheet for the quarter ending April 29 shows that total liabilities totaled 2.9 million, with total debt at $0.84 million. Shareholders hold equity totaling $36.66 million
Let’s look briefly at Timber Pharmaceuticals Inc. (TMBR) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 19.37% to suggest the stock is trending oversold, with historical volatility in this time period at 31.91%.
The stock’s 5-day moving average is $0.7583, reflecting a -12.53% or -$0.1040 change from its current price. TMBR is currently trading -19.56% above its 20-day SMA, -43.72% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -27.31% and -5.10% respectively.
Stochastic %K and %D was 11.83% and 12.40% and the average true range (ATR) pointed at 0.0557. The RSI (14) points at 26.00%, while the 14-day stochastic is at 2.73% with the period’s ATR at 0.0557. The stock’s 9-day MACD Oscillator is pointing at -0.0533 and -0.0878 on the 14-day charts.
Analysts offering their rating for TMBR stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate TMBR as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is TMBR’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $12.00 and a high of $12.00, with their median price target at $12.00. Looking at these predictions, the average price target given by analysts is for Timber Pharmaceuticals Inc. (TMBR) stock is $12.00.